Market Research Outlook on Bile Duct Cancer - Pipeline Review, H1 2016
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.
To view the table of contents and know more details please visit Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016
This report is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG Adgero Biopharmaceuticals, Inc. Agios Pharmaceuticals, Inc. Ariad Pharmaceuticals, Inc. ArQule, Inc. Array BioPharma Inc. Arrien Pharmaceuticals, LLC Aslan Pharmaceuticals Pte. Ltd. Bavarian Nordic A/S Bayer AG Blueprint Medicines Corporation Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Celgene Corporation CellAct Pharma GmbH Cellceutix Corporation Cellular Biomedicine Group, Inc. Concordia Healthcare Corp. Cornerstone Pharmaceuticals, Inc. Delcath Systems, Inc. Eisai Co., Ltd. Eli Lilly and Company Exelixis, Inc. F. Hoffmann-La Roche Ltd. Halozyme Therapeutics, Inc. Innopharmax Inc. Johnson & Johnson Komipharm International Co., Ltd. Loxo Oncology, Inc. Mebiopharm Co., Ltd. MedImmune, LLC Merck & Co., Inc. Merrimack Pharmaceuticals, Inc. NanoCarrier Co., Ltd. NormOxys, Inc. Novartis AG NuCana BioMed Limited OncoTherapy Science, Inc. Ono Pharmaceutical Co., Ltd. Panacea Pharmaceuticals, Inc. PCI Biotech Holding ASA Pfizer Inc. Plexxikon Inc. Provecs Medical GmbH Puma Biotechnology, Inc. RedHill Biopharma Ltd. Sanofi Senhwa Biosciences, Inc. Spectrum Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd. Taiwan Liposome Company, Ltd. tella Inc Threshold Pharmaceuticals, Inc. VasGene Therapeutics, Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:14
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home